Company intelligence / Profile preview

AnPac Bio-Medical Science

Nanjing, Jiangsu, China

Ownership: Public · ANPC
Employees: ~150
Development stage: Other

Overview

AnPac Bio’s proprietary CDA platform allows multi-cancer early risk assessment via blood-based testing; retrospective clinical studies show ability to detect risk for over 20 different cancer types with high sensitivity and specificity; over 300,000 samples processed; commercial revenue from both service and product sales; expansion into COVID-19 diagnostics[10][2][1].

Therapeutic areas: OncologyInfectious Diseases
Modalities: DeviceDiagnostic testImmunological assayGenomics testBiochemical assay
Industry: Molecular Diagnostics

Partnerships

Major US hospital networks (since 2023, for integrating testing into care)medical institutions across China and the US for clinical validation

Financials

Market cap: $27M
Total revenue: $437K
Enterprise value: $37.4M

Beyond the preview

Go deeper on AnPac Bio-Medical Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnPac Bio-Medical Science.

Explore the full profile